If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...

Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...

Expected out-of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...

Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D beneficiaries as drug plans increasingly tie patient costs to list prices, ...

Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...

The two longer-term headwinds facing GLP-1 drugs — Medicare negotiations going into effect in 2027 and the patent cliff for semaglutide in 2032 — are why the company has already started ...

A federal judge will soon decide whether to dismiss a lawsuit against UnitedHealth Group alleging that the company and its ...

The federal health insurance program has selected 15 additional drugs covered by Medicare Part D for its next round of price ...

Rybelsus (semaglutide) is a brand-name prescription ... If a person has an Original Medicare plan and Part D, they will pay a separate monthly premium for Part D in addition to their Part B ...

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...

And the inclusion of the semaglutide drugs — Wegovy for weight ... the biggest reason Novo isn't overly concerned is because Medicare is not its largest market in the US. Until the start of ...